Midcareer Investigator Award in Patient-Oriented Research (Parent K24)

目前的提案是K24职业中期研究者奖的竞争性更新， 马克·S的研究。约翰霍普金斯大学医学院的医学博士Sulkowski说。 博士苏考斯基是约翰霍普金斯大学的一名传染病专业临床研究员 他是一名医学教授，指导着一个高效的临床研究项目， 重点关注艾滋病毒、丙型肝炎病毒（HCV）和药物使用的交叉点。他的研究是 由NIH R 01和NIH资助的艾滋病临床试验组（ACTG）支持;他担任 ACTG肝炎转化科学组主席。他在约翰斯大学期间 霍普金斯，他为革命性的丙型肝炎病毒的发展做出了重大的科学贡献 治疗。他的工作也大大推进了HCV疾病的临床管理， 艾滋病毒感染者。目前的HCV疗法可以治愈95%以上的人 成功地与护理和开始治疗联系起来的人，包括艾滋病毒合并感染者 和吸毒的人然而，在2013年，HCV相关的年度死亡率超过了 疾病控制中心报告的其他60例感染的死亡人数， 包括艾滋病毒。虽然HCV相关的死亡在老年人中最常见， HCV，美国也见证了新的HCV感染在年轻人中的复苏 因为注射鸦片的流行2017年，美国国家医学科学院 结论是，治疗所有慢性HCV感染者将减少90%的新感染， 到2030年，HCV相关死亡人数减少65%。为了实现这一宏伟目标，必须制定预防和 迫切需要在注射毒品的人中治愈HCV。K24的更新对Dr. 苏尔科夫斯基研究这种策略的计划。项目目标包括新的合作研究 评价注射网络在HCV治疗和预防中的作用， 基于HCV临床的丁丙诺啡-纳洛酮增加HCV同时治疗的可行性 和阿片类药物使用障碍。为了实现学院的目标，年轻人 还需要临床研究人员。在最初的K24期间，Sulkowski博士有超过67个 出版物;其中大多数包括年轻的调查人员，他们正在追求职业生涯， 学术研究更新这个K24奖是至关重要的，他希望继续指导初级 研究人员在艾滋病毒和HCV的关键领域，并继续发展他的研究，通过新的 药物滥用研究方面的培训。该裁决所提供的受保护时间对于以下方面至关重要： 博士苏考斯基实现了这些目标。

The current proposal is a competitive renewal of a K24 Midcareer Investigator Award in Patient- oriented research for Mark S. Sulkowski, MD of the Johns Hopkins University School of Medicine. Dr. Sulkowski is an infectious disease-trained clinical investigator at Johns Hopkins University where he is a Professor of Medicine and directs a highly productive clinical research program focused on the intersection of HIV, hepatitis C virus (HCV), and substance use. His research is supported by an NIH R01 and the NIH-funded AIDS Clinical Trials Group (ACTG); he serves as the Chair of the ACTG Hepatitis Transformative Sciences Group. During his time at Johns Hopkins, he has made substantial scientific contributions to the development of revolutionary HCV treatments. His work has also significantly advanced the clinical management of HCV disease in persons living with HIV infection. Current HCV therapies can cure more than 95% of individuals who are successfully linked to care and initiate treatment including individuals with HIV coinfection and those who use drugs. However, in 2013, the annual HCV-related mortality surpassed the combined number of deaths from 60 other infections reported to the Centers for Disease Control, including HIV. While HCV-related deaths are most common in older adults with long-standing HCV, the United States has also witnessed the resurgence of new HCV infections in young adults as the result of the injection opiate epidemic. In 2017, the National Academy of Medicine concluded that treating all persons with chronic HCV would reduce new infections by 90% and HCV-related deaths by 65% by 2030. To achieve this ambitious goal, strategies to prevent and cure HCV in persons who inject drugs are urgently needed. Renewal of this K24 is critical to Dr. Sulkowski's plan to investigate such strategies. Project aims include new collaborative research to evaluate the role of injection networks in HCV treatment and prevention and to assess the feasibility of HCV clinic-based buprenorphine-naloxone to increase concurrent treatment of HCV and opiate use disorders. For progress to be made toward achieving the Academy's goals, young clinical investigators are also needed. During the initial K24 period, Dr. Sulkowski had over 67 publications; the majority of which included young investigators who are pursuing careers in academic research. Renewal of this K24 award is critical to his desire to continue to mentor junior researchers in the key fields of HIV and HCV and to continue to evolve his research through new training in substance abuse research. The protected time afforded by this award is essential to Dr. Sulkowski achieving these goals.